The sale is small relative to market cap and appears to be part of a pre-existing 10b5-1 plan for tax or diversification purposes. Monitor for any acceleration of insider selling beyond the plan's disclosed cadence.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 6 $15.20entry
- T+1 · 8d ago +4.34%α +1.98% · $15.86
- T+5 · 4d ago +9.61%α +7.01% · $16.66
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Kevin McCulloch, an officer of Xeris Biopharma, filed a Form 144 notice of intent to sell 25,000 shares of common stock with an estimated market value of $261,500. The shares were acquired through vesting of restricted stock units, and the filing references a 10b5-1 trading plan with prior sales under that plan in recent months.
Key Facts
- Kevin McCulloch (Officer) filed Form 144 to sell 25,000 shares of common stock.
- Estimated aggregate market value of the proposed sale is $261,500.
- Shares were acquired upon vesting of restricted stock units from January 31, 2024 through January 31, 2025.
- The filing references a 10b5-1 trading plan with prior sales on 09/01/2026, 09/28/2026, 10/01/2026, and 11/02/2026.
- The proposed sale date is listed as 11/05/2026.
Financial Impact
Proposed sale of 25,000 shares valued at $261,500, representing approximately 0.014% of the company's $1.9B market cap.
Risk Factors
- Insider selling, even under a 10b5-1 plan, can signal reduced conviction if it becomes more aggressive than historical patterns.
- The filing is an intent to sell; the actual sale may not occur.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010752 |
| Document: 0001950047-26-010752-index.html | 0001950047-26-010752 |
| Document: 0001950047-26-010752.txt | 0001950047-26-010752 |
Track record
25 reports on XERS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 Now $16.70 +5.30% settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Viewing Entry $15.20 Now $16.70 +9.87% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 4, 202612d ago 3 Neutral 2/10 Entry $13.08 Now $16.70 +27.68% settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 Now $16.70 +61.35% settles Dec 2
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 Now $16.70 +64.21% settles Dec 1
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 Now $16.70 +55.93% settles Nov 30
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 Now $16.70 +70.93% ▲ +69.09% +70.36% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 Now $16.70 +64.86% ▲ +5.73% +8.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers